Physician profile
John P Mann
NPI 1407065063
$1,005.97
in general payments reported to CMS, 2019-2025
15 companies · $287 in 2025
The $287 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $26.67 · 2021: $82.07 · 2022: $97.18 · 2023: $158 · 2024: $63.65 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $386.14 | 2019-2025 | Lens 4k, Double Pump Rf, Pico |
| Stryker Corporation | $153.57 | 2019 | |
| Horizon Therapeutics Plc | $79.67 | 2019-2023 | Krystexxa |
| Kerecis Limited | $63.22 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Zimmer Biomet Holdings, INC. | $57.80 | 2022-2024 | Gel-One Cross-Linked Hyaluronate |
| Abbvie INC. | $57.75 | 2021 | |
| Pacira Therapeutics, INC. | $50.06 | 2019 | |
| Depuy Synthes Sales INC. | $37.23 | 2023 | Monovisc |
| Solventum Corporation | $22.39 | 2025 | Prevena, V.A.C. Veraflo, Activ.A.C. |
| Bioventus LLC | $21.47 | 2022 | |
| Mallinckrodt Enterprises LLC | $20.23 | 2019 | |
| Allergan, INC. | $15.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.23 | 2019 | |
| Heron Therapeutics, INC. | $14.78 | 2022 | |
| Radius Health, INC. | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.